Form 4: BIO-TECHNE Director Receives Equity Grant
Insider Transaction Report
BIO-TECHNE Director John L. Higgins was granted 1,640 shares of common stock and 3,777 stock options on October 30, 2025.
Summary
- John L. Higgins, a Director of BIO-TECHNE Corp (TECH), reported an acquisition of securities.
- On October 30, 2025, 1,640 shares of common stock were acquired at a price of $0, indicating a grant.
- Following this transaction, beneficial ownership of common stock stands at 66,876 shares.
- Additionally, 3,777 stock options were acquired on October 30, 2025, also at a price of $0.
- These new stock options have an exercise price of $60.96 and an expiration date of October 30, 2035.
- The newly granted options will vest on the earlier of October 30, 2026 (one-year anniversary of the grant date) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Sentiment
Score: 5
Explanation: Neutral. This is a routine disclosure of equity compensation for a director, which is a standard practice and does not indicate specific positive or negative operational performance or financial health of the company.
Positives
- The grant of common stock and stock options to a director aligns management's interests with those of shareholders, promoting long-term value creation.
Future Outlook
The newly granted stock options are scheduled to vest on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders.
Industry Context
This filing represents a routine equity compensation event for a director, which is a common practice across industries to incentivize leadership and align their interests with long-term company performance. It does not provide specific insights into broader industry trends or competitive positioning.
Comparison to Industry Standards
- Equity grants to directors are a standard component of compensation packages in publicly traded companies, including those in the biotechnology and life sciences sectors like BIO-TECHNE.
- The grant of shares and options at a $0 price is typical for compensation awards, often tied to performance or service vesting conditions.
- The vesting schedule (one-year anniversary or next annual meeting) is a common structure for director equity awards, aiming to retain directors and align their interests over a reasonable timeframe.
Related Party Transactions
- The acquisition of common stock and stock options by John L. Higgins, a Director of BIO-TECHNE Corp, constitutes a related party transaction as it involves compensation provided to a member of the company's board.
Stakeholder Impact
- Shareholders: The equity grant to a director is intended to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
Next Steps
- The newly granted stock options will vest on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/26/2017 | Date exercisable for 15,940 stock options with an exercise price of $25.30. |
| 10/25/2018 | Date exercisable for 12,500 stock options with an exercise price of $31.26. |
| 10/24/2019 | Date exercisable for 7,592 stock options with an exercise price of $44.96. |
| 10/24/2020 | Date exercisable for 8,044 stock options with an exercise price of $50.41. |
| 10/28/2021 | Date exercisable for 6,028 stock options with an exercise price of $63.92. |
| 10/27/2022 | Date exercisable for 2,532 stock options with an exercise price of $128.81. |
| 10/26/2023 | Date exercisable for 3,460 stock options with an exercise price of $73.94. |
| 10/24/2024 | Date exercisable for 3,937 stock options with an exercise price of $61.51. |
| 10/24/2025 | Date exercisable for 3,511 stock options with an exercise price of $68.37. |
| 10/30/2025 | Transaction date for the acquisition of 1,640 shares of common stock and 3,777 stock options. |
| 11/03/2025 | Date the Form 4 filing was signed and submitted. |
| 10/26/2026 | Expiration date for 15,940 stock options. Also, the one-year anniversary of the grant date for new options, serving as a potential vesting date. |
| 10/26/2027 | Expiration date for 12,500 stock options. |
| 10/25/2028 | Expiration date for 7,592 stock options. |
| 10/24/2029 | Expiration date for 8,044 stock options. |
| 10/29/2030 | Expiration date for 6,028 stock options. |
| 10/28/2031 | Expiration date for 2,532 stock options. |
| 10/27/2032 | Expiration date for 3,460 stock options. |
| 10/26/2033 | Expiration date for 3,937 stock options. |
| 10/24/2034 | Expiration date for 3,511 stock options. |
| 10/30/2035 | Expiration date for the newly acquired 3,777 stock options. |
| 2026 annual meeting | Alternative vesting date for the newly acquired 3,777 stock options, if earlier than October 30, 2026. |
Keywords
BIO-TECHNE, TECH, Form 4, Insider Transaction, Stock Grant, Stock Options, Director Compensation, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.